| abstract |
An anti-PCSK9 monoclonal antibody, an amino acid sequence containing coded antibody variable regions and a CDR regions, a method for obtaining the monoclonal antibody and uses thereof. Monoclonal Antibodies resisting against PCSK9 is obtained from a phage antibody library by means of screening, affinity maturation is achieved by using a method in which a phage antibody library is constructed by means of strand displacement; a library is established to screen mutilations at light-chain CDR1,2,3 regions of the monoclonal antibodies obtained in the initial screening, monoclonal antibodies having high affinity are selected, and then, a library is established to screen mutilations at heavy-chain CDR1,2,3 regions of the monoclonal antibodies having high affinity, and finally, an anti-PCSK9 monoclonal antibody having high affinity is obtained by means of screening. The PCSK9 antibody has good affinity to PCSK9, and can suppress combination of the PCSK9 with a ligand thereof, and can be used for treating dyslipidemia, cardiovascular and cerebrovascular diseases and thrombotic occlusion diseases. |